Stryker Corporation has announced that its OptaBlate® Basivertebral Nerve Ablation System (OptaBlate BVN) has received 510(k) clearance from the U.S. Food and Drug Administration. This clearance marks a significant advancement in Stryker's medical technology portfolio, as OptaBlate BVN is designed to provide relief from chronic vertebrogenic low back pain through a minimally invasive procedure. The system targets the basivertebral nerve using radiofrequency ablation technology, offering long-lasting pain relief for patients. The introduction of OptaBlate BVN is set to be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, Florida.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.